Lilly’s $6.3B Sleep Bet Isn’t About Sleep — It’s About Owning the Next Neuroscience Platform
Eli Lilly just paid $6.3 billion upfront for Centessa Pharmaceuticals and its sleep disorder pipeline. The price looks steep...
Novartis Is Buying the Next Generation of PI3Kα — Before the Current Generation Has Finished Paying Off
Novartis's acquisition of SNV4818 from Synnovation Therapeutics isn't a gap-fill — it's a calculated preemption. In a breast cancer...
AbbVie’s Post-Humira Safety Net Has a Hole in It — and J&J Just Found It
BNP Paribas flagged J&J's oral psoriasis candidate as a credible Skyrizi rival, and Wall Street mostly shrugged. They shouldn't...